Bridge-TIMI 73a Trial: Olezarsen for Hypertriglyceridemia

Bridge–TIMI 73a Trial Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk A randomized, placebo-controlled, double-blind trial Objective:To assess the efficacy and safety of olezarsen for lowering triglyceride levels in patients with moderate hypertriglyceridemia plus elevated cardiovascular risk and in … Read More

FCS BALANCE: Olezarsen in Familial Chylomicronemia Syndrome

FCS BALANCE Trial Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (FCS) A phase 3, double-blind, placebo-controlled trial Objective:To assess the efficacy and safety of olezarsen (given once every 4 weeks) in reducing fasting triglyceride level in patients with familial chylomicronemia … Read More

DEA-HF Trial: Diuretics Regimen in CHF

The infographic details findings from the DEA-HF study, which was designed to evaluate the efficacy and safety of three different diuretic treatment regimens in patients with ambulatory congested heart failure (CHF). The study was conducted in a prospective, randomized, open-label, … Read More

ASSERT Trial: Odevixibat in Alagille Syndrome

ASSERT Trial Highlights Efficacy of Odevixibat in Alagille Syndrome In a significant stride towards better management of Alagille Syndrome, the ASSERT trial has recently showcased promising results for the ileal bile acid transporter inhibitor, Odevixibat. This phase 3, double-blind, randomized, … Read More

E-Cigarettes in Smoking Cessation: A New Tool in the Fight Against Tobacco

Introduction E-cigarettes, also known as electronic cigarettes or vapes, have emerged as a controversial but increasingly popular tool for smoking cessation. As healthcare providers, it’s crucial to understand the potential benefits and risks associated with e-cigarette use, especially in the … Read More

The Therapeutic Potential of Apolipoprotein A1 Infusion in Cardiovascular Disease Management

Introduction Apolipoprotein A1 (ApoA1), the primary protein component of High-Density Lipoprotein (HDL), plays a crucial role in reverse cholesterol transport, a vital process for cardiovascular health. Recent advancements in cardiovascular therapeutics have seen innovative approaches such as ApoA1 infusion, aiming … Read More

ULTIMATE-DAPT: Ticagrelor Monotherapy after ACS

“ULTIMATE-DAPT” trial summary. It presents the results of a clinical trial comparing the use of ticagrelor alone versus the combination of ticagrelor and aspirin following percutaneous coronary intervention (PCI) in patients with Acute Coronary Syndrome (ACS) from month 1 to … Read More

DanGer Shock Trial: Impella in Cardiogenic Shock

“DanGer Shock” study, which is an international, open-label, randomized trial examining the impact of a Microaxial Flow Pump (Impella CP) plus standard care versus standard care alone in infarct-related cardiogenic shock. Objective: To compare the safety and efficacy of Impella … Read More

MANDARA: Benralizumab vs. Mepolizumab for EGPA

“MANDARA” study, a phase 3, double-blind, randomized, active-controlled trial, comparing Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA). Objective: To assess the efficacy and safety of benralizumab as compared with mepolizumab in adults with relapsing or refractory EGPA who … Read More

PAPILLON Trial: Amivantamab in Lung Cancer

Year: 2023 Title: PAPILLON Subtitle: Amivantamab plus Chemotherapy in NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Type of Trial: A Randomized, Open-label Phase 3 trial Objective: To compare the efficacy, as demonstrated by progression-free survival (PFS), in … Read More